Serum cytokeratin 19 fragment, CK19-2G2, as a newly identified biomarker for lung cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Gao, Jia ^a   Lv, Fang ^a   Li, Jia ^a   Wu, Zongyong ^a   Qi, Jun ^a  

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 19 FRAGMENT 2G2; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIGEN CYFRA21.1; CYTOKERATIN 19; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; BLOOD; CHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904035144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101979     Document Type: Article

References (13)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62: 10-29.
2. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, et al. (2006) Non-small cell lung cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network: JNCCN 4: 548-582. (Pubitemid 44265463)
3. Osborn M, Weber K (1982) Intermediate filaments: cell-type-specific markers in differentiation and pathology. Cell 31: 303-306. (Pubitemid 13178853)
4. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24. (Pubitemid 13215192)
5. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, et al. (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer research 53: 61-66. (Pubitemid 23019377)
6. Nisman B, Lafair J, Heching N, Lyass O, Baras M, et al. (1998) Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82: 1850-1859. (Pubitemid 28208639)
7. Gao J, Wang H, Qi J (2008) [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 30: 930-932.
8. Liang ZK, Yin YJ, Wu ED, Shi GL (2013) The clinical value of new tumor biomarker cytokeratin 2G2 detection in non-small cell lung cancer patients. Clinical laboratory 59: 551-556.
9. Ku NO, Omary MB (2001) Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. The Journal of biological chemistry 276: 26792-26798.
10. Sheard MA, Vojtesek B, Simickova M, Valik D (2002) Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. Journal of cellular biochemistry 85: 670-677. (Pubitemid 34462778)
11. Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, et al. (1996) Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. European journal of biochemistry/FEBS 241: 309-314.
12. Barak V, Goike H, Panaretakis KW, Einarsson R (2004) Clinical utility of cytokeratins as tumor markers. Clinical biochemistry 37: 529-540. (Pubitemid 38845016)
13. Kong Y, Wang J, Liu W, Chen Q, Yang J, et al. (2013) Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PloS one 8: e57092.